GENSAIC provides a gene delivery platform using engineered bacteriophage capsids to transport full-length human genes larger than 20 kb into specific cell types. The system offers immune‑privileged, repeat‑dose capability and scalable manufacturing, targeting pharma, biotech and research customers needing large payload capacity for genomic therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current gene therapy vectors, such as viral vectors, face limitations in payload size, manufacturing scalability, and repeat dosing due to immune responses, restricting the range of diseases that can be treated with full-length therapeutic genes.
Solution
GENSAIC leverages engineered bacteriophage capsids to create phage-derived particles (PDPs) that can deliver full-length human genes larger than 20 kb to specific human cell types. By using a minimal phage DNA cargo and modular protein capsids, PDPs enable tissue‑specific targeting, immune‑privileged delivery, and repeat administration without loss of efficacy. The platform is designed for large‑scale, cost‑effective manufacturing, expanding the therapeutic reach of genomic medicines to conditions that require large gene payloads.
Target Audience
Primary customers are pharmaceutical and biotech companies developing gene‑based therapies that require large payload capacity and repeat dosing, as well as research institutions pursuing advanced genomic medicine platforms.
Features
- Engineered bacteriophage capsids that can be customized for cell‑type specific targeting
- Minimal phage DNA (mpDNA) cargo capable of packaging full-length human genes exceeding 20 kb
- Immune‑privileged delivery system allowing repeat dosing with durable therapeutic effect
- Scalable manufacturing process suitable for high‑volume production of gene delivery nanoparticles
- Modular design enabling rapid adaptation to different therapeutic genes and disease indications